Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Bilateral tonic-clonic seizure, Inguinal hernia, Hypoplastic left heart, and Sepsis and others; and very common findings: Macrocephaly and Frontal bossing. 34 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Bilateral tonic-clonic seizure, Convulsive status epilepticus, Severe global developmental delay |
DEPDC5 encodes DEP domain containing 5, GATOR1 subcomplex subunit (1,603 aa). As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway. Highest expression in Ovary (16.3 TPM) and Testis (13.5 TPM).
Developmental and epileptic encephalopathy 111 is associated with mutations in the DEPDC5 gene on chromosome 22.
DEPDC5 is classified as a druggable target with score 0.0.
No consensus clinical diagnostic criteria for DEPDC5-related epilepsy have been published to date.
DEPDC5-related epilepsy should be suspected in individuals with the following clinical, neuroimaging, and EEG findings and family history.
Clinical findings
Source: GeneReviews — "DEPDC5-Related Epilepsy"
No approved treatments are currently available for developmental and epileptic encephalopathy 111. The disease remains an area of unmet medical need.
Gene therapy approaches for developmental and epileptic encephalopathy 111 have been reported in the published literature.
No clinical practice guidelines for DEPDC5-related epilepsy have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with DEPDC5-related epilepsy, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with DEPDC5-Related Epilepsy
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 6.
Recommended Surveillance for Individuals with DEPDC5-Related Epilepsy
System/Concern | Evaluation | Frequency/Indication
No clinical trials have been registered for developmental and epileptic encephalopathy 111.
20 publications have been identified in PubMed for developmental and epileptic encephalopathy 111. Research spans Epidemiology / Natural History (35%), Gene Therapy / Novel Therapeutics (20%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 7 | 35% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 3:22 AM UTC
Online Mendelian Inheritance in Man
Heart and blood vessels |
4 |
Hypoplastic left heart, Sinus tachycardia, Premature ventricular contraction |
Eyes | 3 | Amblyopia, Visual impairment, Horizontal nystagmus |
Lungs and breathing | 2 | Pulmonary artery stenosis, Recurrent respiratory infections |
Head and neck | 1 | Macrocephaly |
Digestive system | 1 | Feeding difficulties |
Blood and immune system | 1 | Recurrent respiratory infections |
Kidneys and urinary system | 1 | Nephrolithiasis |
DEPDC5-related epilepsy encompasses a range of epilepsy syndromes, almost all of which are characterized by focal seizures, with seizure onset in a discrete area of the brain. While about 60% of individuals with DEPDC5-related epilepsy have a normal brain MRI , some have epilepsy associated with a cortical malformation, usually focal cortical dysplasia type II or hemimegalencephaly. Most affected individuals have a family history of focal epilepsy. To date, nearly 200 symptomatic individuals have been identified with a pathogenic variant in DEPDC5 [, , , , , , , , , , , , , , , , , , , , , , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. DEPDC5-Related Epilepsy: Frequency of Select Features in Symptomatic Individuals1
Feature | Feature Subtype (if applicable) | % of Persons w/Feature2 | Comment |
|---|---|---|---|
Epilepsy related complications | All types | 100%3 | Most commonly frontal lobe seizures/ sleep-related hypermotor epilepsy (30%) |
Infantile spasms | 6% | — | — |
SUDEP | 10% | — | — |
Brain malformations | All types | 20% | — |
Focal cortical dysplasia | 17% | Mostly type II | — |
Hemimegalencephaly | 2% | — | — |
Polymicrogyria | 1% | One person was reported w/bilateral polymicrogyria.4 | — |
Developmental/learning issues | Developmental delays (language, motor) | 8% | — |
Intellectual disability | 12% | Most reported persons w/ID have FCD/focal epilepsy or drug-resistant epilepsy. | — |
Developmental delay | 7% | — | — |
Autism spectrum disorder | 5% | FCD = focal cortical dysplasia; SUDEP = sudden unexpected death in epilepsy Asymptomatic heterozygotes are common in families with DEPDC5-related epilepsy. Penetrance is therefore reduced and may be as low as 60% . | — |
Source: GeneReviews — "DEPDC5-Related Epilepsy"
Asymptomatic heterozygotes are common in families with DEPDC5-related epilepsy. Penetrance is therefore reduced and may be as low as 60% .
Source: GeneReviews — "DEPDC5-Related Epilepsy"
The differential diagnosis for DEPDC5-related epilepsy includes other focal epilepsy syndromes as well as other genetic causes of (familial) focal epilepsy and focal cortical dysplasia . Of note, DEPDC5 is the most frequently involved gene among genetic focal epilepsies. Table 3. Genes of Interest in the Differential Diagnosis of DEPDC5-Related Epilepsy
Gene(s) | Disorder | MOI | Clinical Features of Disorder |
|---|---|---|---|
CRH | CHRNA2-, CHRNA4, CHRNB2-, CRH-related ADSHE | AD | Frontal lobe seizures1 |
KCNT1-related epilepsy | AD | EIMFS ADSHE | Persons w/KCNT1-related ADSHE are more likely to develop seizures at a younger age, have cognitive comorbidity, display psychiatric behavioral issues than those w/ADSHE from other causes. LGI1 |
RELN | LGI1- RELN-related ADEAF3 | AD | Focal epilepsy syndrome in which auditory symptoms /or receptive aphasia are prominent ictal manifestations. Affected persons have focal seizures ± altered consciousness; most typical features are auras consisting of humming or buzzing, or more complex auditory hallucinations. |
NPRL2NPRL34 | NPRL2- NPRL3-related focal epilepsy (OMIM 617116 617118) | AD | Familial focal epilepsies incl families w/ADSHE or FFEVF, of which some family members can have FCD type II5 |
MTOR | FCD (OMIM 607341) Smith-Kingsmore syndrome | AD orsomatic | Focal epilepsy, FCD type II, hemimegalencephaly, polymicrogyria |
AKT3 | FCD, hemimegalencephaly, AKT3-related megalencephaly-polydactyly-polymicrogyria-hydrocephalus syndrome6 | AD orsomatic | Focal epilepsy, FCD type II, hemimegalencephaly, polymicrogyria |
Source: GeneReviews — "DEPDC5-Related Epilepsy"
Genetic testing for DEPDC5 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for developmental and epileptic encephalopathy 111 has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Neurologic | Assessment by neurologist for eval of suspected seizures, as indicated | To incl EEG high-resolution brain MRI to evaluate for focal cortical dysplasia or other brain malformations Assessment for predictive factors for SUDEP1 |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Genetic counseling | By genetics professionals2 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of DEPDC5-related disorders to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with DEPDC5-Related Epilepsy Manifestation/Concern | Treatment | Considerations/Other |
Epilepsy | Standardized treatment w/ASM by experienced neurologist | Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.; Education of parents/caregivers1 |
Brain malformations | Resective epilepsy surgery may be considered in persons w/focal epilepsy that is refractory to medical therapy. | In those w/FCD or hemimegalencephaly, epilepsy surgery should be explored early in disease course.; Surgical outcomes have been variable.2 Developmental delay/ |
Intellectual disability | Standard treatment, which may incl supportive developmental therapies (OT, PT, ST) to address specific delayed areas | Consultation w/neurodevelopmental specialist may be considered. Autism spectrum disorder |
Family/Community | Ensure appropriate social work involvement to connect families w/local resources support. | ABA = applied behavior analysis; ASM = anti-seizure medication; FCD = focal cortical dysplasia; OT = occupational therapy; PT = physical therapy; ST = speech therapy Education of parents/caregivers regarding common seizure presentations is appropriate. |
Recommended Surveillance for Individuals with DEPDC5-Related Epilepsy System/Concern | Evaluation | Frequency/Indication |
Neurologic | Assess for new or ongoing manifestations, such as new-onset seizures /or changes in seizures or tone. | At each visit Repeat brain MRI (incl higher-resolution brain MRI). |
Development | Monitor developmental progress. | At each visit |
Source: GeneReviews — "DEPDC5-Related Epilepsy"
View trials for developmental and epileptic encephalopathy 111
Assess for predictive factors for SUDEP.1
Repeat brain MRI (incl higher-resolution brain MRI). | For those w/treatment-resistant seizures whose first brain MRI was normal
Repeat EEG. | To address any in seizure frequency or new seizure symptomatology
| Monitor developmental progress. | At each visit
| Assess family need for social work support, care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).
SUDEP = sudden unexpected death in epilepsy
1. Predictive factors may include frequent generalized clonic-tonic seizures.
Source: GeneReviews — "DEPDC5-Related Epilepsy"
Phenotype severity distribution: 20 always present features, 2 very common features, 3 common features.
New treatment approaches |
4 |
20% |
Research summaries | 2 | 10% |
Patient case studies | 2 | 10% |
Clinical study results | 2 | 10% |
Laboratory research | 2 | 10% |
Testing and diagnosis research | 1 | 5% |
Balestrini S (2026). [PMID: 41137852](https://pubmed.ncbi.nlm.nih.gov/41137852/). *Epilepsia*. [Epidemiology / Natural History]
Surabhi P (2026). [PMID: 42269414](https://pubmed.ncbi.nlm.nih.gov/42269414/). *Seizure*. [Epidemiology / Natural History]
Zhang G (2026). [PMID: 41133935](https://pubmed.ncbi.nlm.nih.gov/41133935/). *Epilepsia*. [Gene Therapy / Novel Therapeutics]
Liogier d'Ardhuy X (2026). [PMID: 41531035](https://pubmed.ncbi.nlm.nih.gov/41531035/). *Epilepsia*. [Epidemiology / Natural History]
Piper RJ (2026). [PMID: 41553602](https://pubmed.ncbi.nlm.nih.gov/41553602/). *Epilepsia*. [Clinical Trial Publication]
Amin S (2025). [PMID: 40493384](https://pubmed.ncbi.nlm.nih.gov/40493384/). *JMIR Form Res*. [Epidemiology / Natural History]
Kaki A (2025). [PMID: 40515869](https://pubmed.ncbi.nlm.nih.gov/40515869/). *Neurogenetics*. [Case Report / Case Series]
Barsh GR (2025). [PMID: 40350215](https://pubmed.ncbi.nlm.nih.gov/40350215/). *Clin Perinatol*. [Review / Meta-Analysis]
DeGasperis S (2025). [PMID: 40849994](https://pubmed.ncbi.nlm.nih.gov/40849994/). *Epilepsy Res*. [Diagnostic / Biomarker]
Vikin T (2025). [PMID: 39797741](https://pubmed.ncbi.nlm.nih.gov/39797741/). *Epilepsia*. [Epidemiology / Natural History]